🇺🇸 FDA
Pipeline program

Dendritic cell immunotherapy

DC3-HRPC, October 2001

Phase 3 small_molecule terminated

Quick answer

Dendritic cell immunotherapy for Prostate Cancer is a Phase 3 program (small_molecule) at NORTHWEST BIOTHERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NORTHWEST BIOTHERAPEUTICS INC
Indication
Prostate Cancer
Phase
Phase 3
Modality
small_molecule
Status
terminated

Clinical trials